Senior Writer, National Biotech Columnist
Adam Feuerstein is a Senior Writer and National Biotech Columnist. He specializes in medicine and healthcare, with a focus on oncology, pancreatic cancer research, pharmaceutical regulation, immunotherapy, hematology, gene therapy, and mental health care. Adam's work has been featured in The Boston Globe, RamaOnHealthcare, STAT News, and TheStreet.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Adam Feuerstein's coverage primarily revolves around the healthcare and pharmaceutical industry, with a strong emphasis on providing data-driven insights and expert commentary. He frequently references press releases and cites data to support his reporting.
To effectively reach out to Adam, consider offering access to exclusive data or research findings related to biotech, healthcare, pharmaceuticals, drug development, or FDA approval processes. Additionally, experts who can provide insightful analysis of industry trends or specific events will likely capture his attention.
As Adam's geographic focus is not specified but he covers global pharmaceutical and biotech industries extensively; therefore relevant information from any part of the world would be valuable for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Why the extra-long delay on a review of Northwest Biotherapeutics' brain cancer treatment?
By: Adam Feuerstein, Elaine Chen, Allison DeAngelis
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor?
This story first appeared in Adam's Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The deal, worth $2.8 billion upfront, will expand Lilly's neuroscience portfolio and extend its recent acquistion run
By: Adam Feuerstein, Allison DeAngelis, Elaine Chen
On this week's episode of “The Readout LOUD”: The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer's disease treatment from Biogen.
By: Adam Feuerstein
A former doctor accused of sexual assault but on the run for 20 years appears to have been living a secret life as a biotech executive.
By: Adam Feuerstein
ProMIS Neurosciences thinks it can clear amyloid from the brain with lower side effect risks than approved medicines
By: Adam Feuerstein
W When one of Rhode Island's most-wanted fugitives was discovered last week to have been secretly working under an alias in the biotech industry , the reaction among many was shock.
By: Andrew Joseph, Adam Feuerstein
Therapy has been closely watched by patient community, investors
By: Allison DeAngelis, Adam Feuerstein, Elaine Chen
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?
